Notes / Company Suven Life Sciences Ltd. SUVEN BSE 530239 ISIN INE495B01038 Pharmaceuticals Fundamentals Market cap₹7,026 cr ROE0.00% Debt / equity0.00 52-week range 124.35 — 303.00 The timeline — 1 note on Suven Life Sciences Ltd. June 2026 04 Jun 26 · 10:56 AM IST Lead Lead · Mid cap Suven's Alzheimer's drug passes a critical Phase 3 safety check. An independent board reviewed halfway data and told Suven to press on without changing the trial design or size. Enrollment is now at 88%. Verify on exchange BSE filings for SUVEN NSE filings for SUVEN